Media Newsroom of

Bridge Therapeutics

Birmingham, AL

Bridge Therapeutics, Inc. is an innovative development-stage pharmaceutical company pursuing FDA and EMA approval of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients.

Pharma Startup, Bridge Therapeutics, to Participate in American Chronic Pain Association Roundtable With Agenda for Chronic Pain Drug Development Program

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they will be introducing their chronic pain development program at the American Chronic Pain Association (ACPA) Roundtable. The ACPA offers peer support and education in pain management skills to…

Pharma Startup, Bridge Therapeutics, Will Unveil Its Chronic Pain Drug Development Program at the 2018 youngStartup Ventures Summit in New York

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they would showcase their chronic pain drug development program to venture capitalists at the 2018 youngStartup Ventures Summit in New York. More than 150 venture capitalists will hear pitches…

Pharmaceutical Startup, Bridge Therapeutics, Announces It is Funding a Mini-Documentary That Will Educate the Public on the Dangers of Opioids

​The innovative late development-stage pharmaceutical startup, Bridge Therapeutics has announced it is sponsoring a mini-documentary that will educate the public on the use and misuse of opioid prescriptions. Tim Peara, Director of Finance for Bridge Therapeutics, said the campaign will alert the community…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login